Larry Lands and Laurent Pharmaceuticles to begin a clinical trial on COVID-19 treatment with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus

Laurent Pharmaceuticals to begin clinical trial on COVID-19 treatment

Click here to read how Laurent Pharmaceuticals, a McGill spinoff will run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus.

Larry Lands is the Chief Medical Advisor for Laurent Pharmaceuticals. Laurent Pharmaceuticals Inc. is planning to test its lead drug LAU-7b in patients with COVID-19 disease. LAU-7b was recently identified as a potential anti-viral therapeutic option for COVID-19 during a drug-library screening effort.